DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / Medical Excellence Capital, LLC
Medical Excellence Capital, LLC
MEC is an early-stage life sciences venture fund deploying precision capital to advance precision health innovations.
venture manager, reported GAV $146M across 1 vehicles
Importance
22
moderate
Active deployment
8
low
Emerging
0
low
Completeness
63
high
Freshness
100
high
Research priority
6
low
Identity and regulatory footprint
- Headquarters
- unknown
- Office address
- unknown
- Business phone
- (917) 512-5441adviserinfo.sec.gov
- Website
- https://www.medexcelcap.com
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Mar 6, 2026
- Private funds reported
- 1 (1 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $146Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- Owners on Schedule A
- Siracusa, LLC (Managing Member Of Medical Excellence Capital Llc And Medical Excellence Gp Llc), E; ICT Holdings Ltd. (Member Of Medical Excellence Capital Llc And Medical Excellence Gp Llc), A
- business email
- info@medexcelcap.commedexcelcap.compublished by the subject
- business phone
- (917) 512-5441adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
2 observed deals
Stated (the firm’s website)
- Sectors
- ai, biotech, space
- Stages
- seed, series a, series b, early
- Geography
- not stated
- Check size
- not stated; DFX does not estimate checks from round sizes
- Self-described
- venture capital
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors
unknown 100%
lead rate n/afollow-on rate n/anew logos, 12 months 2
Funds and vehicles
1 reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| Medical Excellence Capital Partners, LP | Fund | unknown | Unknown | $146M Dec 16, 2024 | 11 | unknown | unknown |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
14 current, 0 departed
Victoria Lewis
AssociateResearch Associate
Brian Halak
Board or advisorySenior Advisor
Joan Marie Mancini
General partnerChief Financial Officer And Regulatory Contact Of Medical Excellence Capital Llc And Medical Excellence Gp Llc · since Nov 1, 2020
John Patrick Hornbostel
General partnerCounsel Of Medical Excellence Capital Llc And Medical Excellence Gp Llc · since Nov 1, 2020
Eric Heil
Managing partnerManaging Partner
John Prufeta
Managing partnerManaging Member Of Medical Excellence Capital Llc And Medical Excellence Gp Llc · since Aug 1, 2020
John Prufeta
Managing partnerFounder, CEO & Managing Partner
Joni Mancini
Managing partnerManaging Partner
Kim Kamdar
Managing partnerManaging Partner
Annabel Stoddart
OtherChief of Staff
John Hornbostel
OtherCounsel
Tess Marvin
OtherScientific Investment Strategist
Olga Prufeta
PartnerOlga Prufeta has served as Limited Partner (LP) Liaison for Medical Excellence Capital (MEC) since its inception.
Max Colbert
Vice presidentSenior Associate
Investments on record
2 edges, 2 companies, 0 partner-attributed
| Company | Round | Role | Partner | Round size | This investor | Date | Source |
|---|---|---|---|---|---|---|---|
| SYN001 – Arctic Therapeutics | portfolio listing | unknown | unknown | unknown | unknown | Sep 16, 2026 | Fact Venture organization websites (about, team, portfolio, thesis, news pages) |
| Trotana Therapeutics | portfolio listing | unknown | unknown | unknown | unknown | Sep 16, 2026 | Fact Venture organization websites (about, team, portfolio, thesis, news pages) |
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
1 relationships from shared deals, counted for the whole firm
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
2 dated events
- Dec 23, 2021Medical Excellence Capital, LLC first filed Form ADV (ERA, venture capital fund adviser exemption)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Dec 23, 2021Medical Excellence Capital Partners, LP first reported on Form ADV by Medical Excellence Capital, LLC (Venture Capital Fund), GAV $104,300,000Fund first reported on Form ADVFundsFactMedical Excellence Capital Partners, LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
- Sep 12, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $146M across 1 vehicles
Evidence
44 observations from 3 sources